TITLE

Letter from the Executive Director

AUTHOR(S)
Caldwell, Katy
PUB. DATE
December 2012
SOURCE
Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
An introduction is presented in which the author discusses various reports within the issue including one about adherence to Truvada as pre-exposure prophylaxis (PrEP), another one about a PrEP trial in gay and bisexual men and transgender women, and one about integrating PrEP into practice.
ACCESSION #
89368689

 

Related Articles

  • A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. Corneli, Amy L.; McKenna, Kevin; Headley, Jennifer; Ahmed, Khatija; Odhiambo, Jacob; Skhosana, Joseph; Meng Wang; Agot, Kawango // Journal of the International AIDS Society;2014 Supplement 2, Vol. 17 Issue Supp 2, p1 

    Introduction: Risk perception is a core construct in many behaviour change theories in public health. Individuals who believe they are at risk of acquiring an illness may be more likely to engage in behaviours to reduce that risk; those who do not feel at risk may be unlikely to engage in risk...

  • Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Havens, Peter L; Perumean-Chaney, Suzanne E; Patki, Amit; Cofield, Stacey S; Wilson, Craig M; Liu, Nancy; Anderson, Peter L; Landovitz, Raphael J; Kapogiannis, Bill G; Hosek, Sybil G; Mulligan, Kathleen // Clinical Infectious Diseases;2/15/2020, Vol. 70 Issue 4, p687 

    Human immunodeficiency virus–seronegative men aged 15–22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z...

  • Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. Wilton, James; Senn, Heather; Sharma, Malika; Tan, Darrell H. S. // HIV/AIDS - Research & Palliative Care;2015, Vol. 7, p125 

    Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals...

  • Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Hurt, Christopher B.; Eron Jr., Joseph J.; Cohen, Myron S. // Clinical Infectious Diseases;12/15/2011, Vol. 53 Issue 12, p1265 

    Pre-exposure prophylaxis (PrEP), the use of antiretrovirals (ARVs) by human immunodeficiency virus (HIV)- uninfected individuals to prevent acquisition of the virus during high-risk sexual encounters, enjoyed its first 2 major successes with the Centre for the AIDS Programme of Research in South...

  • Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study. Nichols, Brooke E.; Boucher, Charles A. B.; van Dijk, Janneke H.; Thuma, Phil E.; Nouwen, Jan L.; Baltussen, Rob; van de Wijgert, Janneke; Sloot, Peter M. A.; van de Vijver, David A. M. C. // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Background: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The optimal scenario for implementing PrEP where most infections are averted at the lowest cost is unknown. We determined the impact of different PrEP strategies on averting new...

  • THE HIV YEAR IN REVIEW. ANDERSON-MINSHALL, DIANE // Advocate;Dec2014/Jan2015, Issue 1076, p45 

    A timeline is presented of HIV- and AIDS-related events in 2014 including German scientists who reported extracts from the geranium plant Pelargonium sidoides can block HIV from entering human cells, University of Missouri researchers who reported a molecule in soy sauce, EFdA, could be used to...

  • Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection. Lyseng-Williamson, Katherine A.; Scott, Lesley J. // Clinical Drug Investigation;2012, Vol. 32 Issue 10, p715 

    The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Evipleraâ„¢ [EU]; Compleraâ„¢ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient...

  • Who's prepared to make PrEP work? Mascolini, Mark // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p5 

    Tenofovir/emtricitabine (TDF/FTC) won FDA approval for preexposure prophylaxis (PrEP) after three placebo-controlled trials demonstrated that once-daily TDF/FTC lowers HIV acquisition risk in gay and bisexual men and heterosexual women and men. In the one trial that found no HIV protection with...

  • HIV Pre-exposure Prophylaxis: Clinical Implications and Real-World Effectiveness. Julius Li; Dufren, Staci L.; Okulicz, Jason F. // Journal of AIDS & Clinical Research;2012, Vol. 3 Issue 9, Special section p1 

    The use of tenofovir-emtricitabine as pre-exposure prophylaxis (PrEP) represents the latest strategy to prevent the acquisition of HIV by uninfected individuals. Despite clinical trials exhibiting significant risk reductions with PrEP, several limitations may hinder its real-world effectiveness....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics